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TRANSGENIC MICE WHICH
OVEREXPRESS NERVE GROWTH FACTOR

murine insulin-like growth factor-1 and -2 gene, the murine
ot-transforming growth factor gene with a murine hst/KS3
gene. The transgenic mice of Leder et al. exhibit prostate

This application is a continuation of application Ser. No.
08/131,424 ?led Oct. 4, 1993, now abandoned.

hyperplasia and give sterile o?fspring.
U.S. Pat. No. 5,175,384 to Krimpenfort et al. discloses

transgenic mice having a phenotype characterized by the
TECHNICAL FIELD

substantial absence of mature T-lymphocytes. The mouse is
produced by introducing a transgene into a zygote of a
mouse which comprises gene fragment which encodes a

The present invention relates to transgenic mice that
express increased levels of nerve growth factor (NGF) in the

10

epidermis and other strati?ed, keratinized epithelium. The
nerve growth factor expressing transgenic mice of the

mouse.

present invention are valuable to researchers that study the
role of nerve growth factor and other neurotrophic factors in
the development and function of the nervous system, and in
the study of neurodegenerative disorders of the brain such as

U.S. Pat. No. 5,175,385 to Wagner et al. discloses the
production of a transgenic mouse with enhanced viral resis
tance which is transmissible to its o?°spring. The transgenic
mouse is prepared by introduction of a gene encoding a

Parkinson’s syndrome and Alzheimer’s disease.

human interferon having anti-viral activity into a host
mouse. The plasmid of Wagner et al. contains a methal—
lothionein-l promoter and the genomic human beta inter

BACKGROUND
20

The survival of developing vertebrate neurons is thought
to be dependent on access to a limited supply of target

than did the control animals.

the most extensively characterized of these factors and has
been shown to regulate the survival of discrete populations

25

of neurons.

U.S. Pat. No. 4,185,095 to Young discloses the isolation

salivary gland.

U.S. Pat. No. 5,082,774 to Heinrich discloses a recom
binant human nerve growth factor. The nerve growth factor
is in an expression vector with an adenovirus strong, major,
late promoter. Heinrich discloses that the expression vector
may be used to stably transfect mammalian cells such as

30

CHO or COS cells.

35

U.S. Pat. No. 5,180,820 to Barde et al. discloses that NGF

has been molecularly cloned.
Various transgenic mice have been patented. U.S. Pat. No.
40

animal or an ancestor of the animal at an embryonic stage.

The embryo of the mice were rnicroinjected with approxi

mately 500 copies of the RSVS-107 c-myc plasmid. The

45

contains a Rous Sarcoma Virus enhancer and promoter

sequence. The resultant mice showed expression of the

c-myc gene in the salivary gland, spleen, testes, lung, brain,
and preputial gland and intestinal tissue.
U.S. Pat. No. 5,175,383 to Leder et al. discloses a male
which contain a recombinant gene which is a vertebrate gene

55

construction of transgenic mice using a plasmid which
contains the K14 keratin promoter and the TGF-ot gene.
Vassar et al. disclose that the TGF-Ot gene belongs to the

epidermal growth factor family of proteins and shows struc
tural homology with the epidermal growth factor. These
transgenic mice showed gross phenotypic abnormalities in
their skin including ?aky outer epidermal layers with stunted
hair growth and wrinkling. The plasmid used to create this
transgenic mouse also included human growth hormone
fusion gene.
Patil et al. in Neuron, Volume 2, pages 347-447, March

Nerve Growth Factor Receptors in the Basal Forebrain and
Cerebellum of Transgenic Mice”. Patil et al. employed a
cosrnid clone containing the entire NGF receptor gene.
Introduction of the human NGF receptor gene into the
mouse germ line resulted in signi?cant levels of expression
in speci?c cells in both the peripheral and central nervous

Science, Volume 89, pages 2764-2768, April 1992, disclose
60

“Pituitary Hyperplasia Induced by Ectopic Expression of
Nerve Growth Factor”. Borrelli et al. fused nerve growth
factor cDNA to rat prolactin promoter to induce its ectopic

greater than 50% homologous in terms of encoded amino
acid sequence) a naturally occurring, vertebrate gene in the

Int-2/FGF gene family of murine growth factor encoding
genes or their vertebrate counterparts, including the murine
acidic or basic ?broblast growth factor genes, the murine
FGF-S gene, the murine epidermal growth factor gene, the

transgenic mice.
Vassar et al. in Gene & Development, Volume 5,. pages
714-727, (1991) disclose “Transgenic Mice Provide New
Insights into the Role of TGF~(X During Epidermal Devel
opment and Differentiation”. This publication discloses the

systems. The NGF receptor gene and the NGF gene are

a promoter sequence controlling transcription of the recom

nant gene is preferably substantially homologous with (i.e.,

tide substance P and determined the expression of the
plasmid and neuropeptide substance P in the tail skin of

distinct genetic material.
Borrelli et al. in Proceedings of the National Academy of

binant gene such as a promoter derived from the mouse

mammary tumor virus and cytomegalovirus. The recombi

Mice”. This publication discloses that Vassar et al. used a
plasmid containing a K14 keratin promoter and a neuropep~

1990, disclose “Speci?c Neuronal Expression of Human
50

transgenic mouse containing germ cells and somatic cells

in the Int-2/FGF family which is capable of promoting
benign prostatic hyperplasia or hypertrophy. The fusion gene
which is injected into the mouse embryonic tissue comprises

Vassar et al., in the Proceedings of the National Academy
of Sciences, Volume 86, pages 1563-1567, March 1989,
disclose ‘Tissue-speci?c and Dilferentiation-speci?c
Expression of a Human K14 Keratin Gene in Transgenic

of a nerve growth factor from mouse submandibular or

4,736,866 to Leder et al. discloses a transgenic non~human
eukaryotic animal whose germ cells and somatic cells con
tain an activated oncogene sequence introduced into the

feron gene. When these mice were injected with pseudora~
bies virus they showed an increased resistance to the virus

and although many mice died they died considerably later

derived neurotrophic factors. Nerve growth factor (NGF) is

injected eggs were transferred to pseudopregnant foster
families and allowed to develop to term. The plasmid

T-cell antigen receptor polypeptide variant which is inca
pable of mediating T-cell maturation in the transgenic

65

expression in pituitary lactotrophs of transgenic mice.
Federoif et al. in Proceedings of the National Academy of
Science, USA, Volume 89, pages 1636-1640, March 1992,
disclose “Expression of Nerve Growth Factor in Vivo from
a Defective Herpes Simplex Virus~1 Vector Prevents Effects
v

5,602,309
3
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of Axotomy on Sympathetic Ganglia”. This publication

in vivo approaches in which NGF peptide or NGF antibodies
were applied. (See Levi-Montalcini and Booker, 1960,

teaches that rat nerve growth factor packaged into a herpes

simplex virus-l particle after axotomy of sympathetic supe

supra; Johnson, E. M., Gorin, P. D., Brandeis, L. D., Pear

rior cervical ganglion prevented a decline in the tyrosine

hydroxylase level which is generally required for mainte

son, J. (1980). Dorsal root ganglion neurons are destroyed
by exposure in utero to maternal antibody to nerve growth

nance of the noradrenergic neurotransmitter system.
Edwards et al. in the Cell, Volume 58, pages 151-170, Jul.

factor. Science 210, 916-918; Barde, Y. A., Edgar, D.,
Thoenen H. (1980). Sensory neurons in culture: Changing

14, 1989, disclose “Directed Expression of NGF to Pancre
atic B Cells in Transgenic Mice Leads to Selective Hyperin

requirements for survival factors during embryonic devel
opment. Proc. Natl. Acad. Sci. U.S.A. 77, (1980) 1199-1203;
Hamburger, V. and Yip, H. W. (1984). Reduction of experi
mentally induced neuronal death in spinal ganglia of the
chick embryo by nerve growth factor. J. Neurosci. 4,

nervation of the Islets”. Edwards et al. showed a selective 10

increase the expression of NGF in pancreatic [3 cells by

creating a hybrid gene that contained a rat insulin promoter
fused to mouse NGF cDNA followed by an intron and

767-774). Sympathetic and certain sensory neurons can be
reduced by exogenous NGF whereas anti-NGF antibodies

transcriptional terminator from the SV40 virus.

eliminate these neurons.

PCT Publication WO 93/00909 is directed to a method of

During development of skin, NGF is expressed by target
cells of the presumptive epidermis and dermis. (See Davies,

treating neurotrophin-expressing tumors by administering a
sequence complementary to at least a portion of a RNA

A. M., Bandtlow, D., Heumann, R., Korsching, S., Rohrer,

transcript of brain-derived neurotrophic factor gene.

H., and Thoenen, H. (1987). Timing and site of nerve growth
factor synthesis in developing skin in relation to innervation
and expression of the receptor. Nature 326, 353-358).
Target-?eld synthesis of NGF coincides with the arrival of

During development of the vertebrate nervous system up
to half of all neurons generated undergo a process of

naturally occurring cell death (See Ard, M. D., Morest, D. K.
(1984). Cell death during development of the cochlear and
vestibular ganglia of the chick. Intl. J. Dev. Neurosci. 2,
535-547; and Oppenheim, R. W. (1991). Cell death during

axons to the epidermis, though the onset of expression as
well as the concentration of NGF are independent of inner

development of the nervous system. Ann. Rev. Neurosci. 14,

453-501).

25

Neuronal death typically occurs shortly after neurons

being making functional connections within their target
?eld. Survival during this period of innervation is thought to
be dependent on the synthesis by the target tissue of a

vation. (See Rohrer, H., Heumann, R., Thoenen, H. (1988).
Synthesis of nerve growth factor (NGF) in developing skin
is independent of innervation. Dev. Biol. 128, 240-244; and
Harper, S. .l., and Davies, A. M. (1990). NGF mRNA
expression in developing cutaneous epithelium related to

innervation density. Development 110,515-519). Thus, cells
of the target ?eld appear to control the onset and level of

limited quantity of neurotropic substances. (See Thoenen, H.
and Barde, Y. A. (1980). Physiology of nerve growth factor.

NGF gene expression.

Physiol. Rev. 60, 1284-1334; Oppenheim, R. W. (1989). The
neurotrophic theory and naturally occurring motoneuron

vation have shown that by embryonic day 11 (E11) axons

In mouse whisker pad skin, time course studies of inner
have grown out to the skin and NGF mRNA expression has

death. Trends in Neurosci. 12, 252-255; and Davies, A. M.,

Larmet, Y., Wright, E., Vogel, K. S. (1991). Coordination of
trophic interactions by separate developmental programs in

35

NGF concentration coincides with the onset of death of

sensory neurons and their target ?elds. J. Cell Sci. 15,

111-116)).
The competition for- target ?eld-derived neurotrophic
factors is though to serve at least two functions: to ensure 40
that an appropriate number of synaptic contacts are made at

the target and to eliminate inappropriate neuronal projec
tions. (See Oppenheim, R. W. (1981). Neuronal death and
some related phenomena during neurogenesis. In Studies in

Developmental Biology (ed. W. M. Cowan) p 74-133.
Oxford University Press; and Cowan, W. M., Fawcett, J. W.,
O’Leary, D.D.M., and Stan?eld, B. B. (1984). Regressive
events in neurogenesis. Science 225, 1258-1265)).

45

This concept is referred to as the neurotrophic hypothesis
and predicts that the number of neurons in the adult could be

increased if a higher concentration of neurotrophic factor(s)
was available during the critical time when synaptic contacts
are being established.
Nerve growth factor (NGF) is a prototypical target-de
rived neurotrophic substance that has been shown to be

begun. (See Davies et al., 1987, supra). NGF continues to
rise until E14 and then falls sharply by E15. The decrease in
nearly half of the neurons in the trigerninal ganglion.
As skin innervation proceeds, the embryonic epithelium
begins the transformation from a two-cell layer, undifferen
tiated periderm to a multilayer, strati?ed epidermis. (See
Schweizer, J ., and Winter, H. (1982). Keratin polypeptide
analysis in fetal and in terminally differentiating newborn
mouse epidermis. Di?erentiation 22, 19-24; and Kopan, R.
and Fuchs, E. (1989). A new look into an old problem:
Keratins as tools to investigate determination, morphogen
esis, and differentiation in skin. Genes and Devel. 3, 1-15).
The differentiation of the epidermis is marked by the
expression of epidermal speci?c genes, one of the earliest
being the gene encoding the keratin intermediate ?lament
protein K14. The onset of K14 gene expression in mouse

skin occurs at approximately E14-E15 (see FIG. 1(b), begin
ning as NGF concentration is declining.
Heretofore there has been no convenient method to inves
55

tigate how target-derived NGF affects neuron survival and
development of the peripheral nervous system or provide a

essential for the survival and differentiation of neural crest
derived sensory neurons, sympathetic neurons, and fore
brain cholinergic neurons. (See Levi-Montalcini, R. and

practical model for testing drug candidates for the treatment

Neurosci. 6, 2155-2161; Williams, L. R., Varon, S., Peter
son, 6., Wictorin, K., Fischer, W., Bjorklund, A. & Gage, F.
H. (1986). Proc. Natl. Aced. Sci. U.S.A. 83, 9231-9235).

hyperinnervation.

of neurodegenerative disorders of the brain such as Parkin
son’s syndrome and Alzheimer’s disease.
Booker B. (1960). Destruction of the sympathetic ganglia in 60
The present invention overcomes the de?ciency by pro
mammals by an antiserum to a nerve-growth protein. Proc.
viding transgenic mice that manufacture increased levels of
Natl. Acad. Sci. USA 46, 384-391 and Hefti, F. (1986) J.
NGF in the basal keratinocytes of the skin and exhibit

The role of NGF in neuron survival is supported by
numerous studies that have utilized both tissue culture and

65

DISCLOSURE OF THE INVENTION
The invention provides a transgenic mouse whose somatic
and germ cells contain and express a gene encoding for

5

5,602,309
6

nerve growth factor. The gene exhibits hyperinnervation in
the mouse, and has been introduced into a mouse or an

FIGS. 5a—d: FIG. 5 shows immunolabeling of transgenic
skin reveals a hyperinnervation of sensory and sympathetic

ancestor of the mouse at an embryonic stage. The NGF gene
is operatively linked to a human K14 keratin promoter and

composed of neuronal processes, frozen sections of whisker

enhancer region.

pad skin from control (FIG. 5a) and A-56 Fl transgenics

The invention also provides for a mouse wherein the NGF
gene has been introduced into an ancestor if said mouse at

(FIG. 5b) were immunolabeled with an anti-neuro?lament

neurons. To verify that the ?ber bundles in the skin were

150 antibody followed by incubation with a goat anti-rabbit
FITC conjugated secondary. A signi?cant increase in the

an embryonic stage by microinjection.

number of ?bers and bundles was seen in an equivalent

In an additional embodiment, the mouse nerve growth

factor is further operatively linked to the human growth
hormone gene.

10

The invention provides for a mouse which has a pheno

region of A56 transgenic skin (FIG. 5b). A-56 skin con
tained sympathetic ?bers, sections were immunolabeled
with an anti-TH antibody followed by a biotinylated goat

anti rabbit secondary processing with DAB (FIG. Sc). A-56

type characterized by hyperinnervation of the skin, hyper

F1 transgenics labeled with anti-CGRP followed by a bioti

trophy of trigeminal ganglion and enlargement of the supe
rior cervical sympathetic and dorsal root ganglia.
Advantageously, the present invention provides a method
of producing the transgenic mouse which overexpresses
nerve growth factor which comprises

nylated goat-anti rabbit secondary antibody are shown in
FIG. 50!.
FIGS. 6a, b: FIG. 6 shows expression of K14-NGF causes

enlargement of the trigeminal and superior cervical ganglia.

Trigeminal ganglia (FIG. 6a) and superior cervical ganglia

(a) providing a mouse nerve growth factor gene opera 20 (FIG. 6b) were removed from control A~48 F1, and A-56 Fl
tively linked to a human K14 keratin promoter and enhancer
mice.
region functional in said mouse;
(b) introducing said gene into a mouse embryo;
STATEMENT OF DEPOSIT

(c) transplanting said embryo into a pseudopregnant
mouse; and

25

the ef?cacy of drugs in treating neurodegenerative disorders
comprising administering said drug to a mouse according to 30
the invention, and determining the behavioral effects and
tissue changes of said drug on said mouse.

35

FIGS. 1a, b, 0: (FIG. 1(a) shows the K14-NGF fusion
gene contains the mouse NGF cDNA cloned downstream

The mice are obtained by making a fusion gene construct
in which the human K14 keratin promoter and enhancer

To increase the expression of the transgene, a region from
the human growth hormone gene may, in a preferred
embodiment, be added to the construct. Production of nerve
growth factor in the epidermis of these mice was found to

result in a profound hyperinnervation of the peripheral
nervous system, i.e. skin has increased nerve ?bers, the

obtained three to four weeks after birth. Blots were probed
45

mouse NGF cDNA.

FIGS. 2a, b: FIG. 2(a) examines the expression level of
the K14-NGF transgene for transgenic mouse lines. Shown
is a 3 d exposure, FIG. 2(a) and a 10 d exposure, FIG. 2(b),
of the same ?lter. FIG. 2(b) examines the tissue speci?city

of K14-NGF expression.

55

whisker pad epidermis, FIG. 3(a), and vibrissa, FIG. 3(0), of
control animals had silver grain density at background
levels. A-56 Fl transgenic mice had a greater labeling
density of whisker pad basal cells, FIG. 3(b) (arrows), and
vibrissa, FIG. 3(d).
FIG. 4 shows expression of K14-NGF causes hyperinner~
vation of skin. Skin from dorsum, (FIGS. 4a and 4b) and
whisker pad (FIG. 40 and 4d) was processed for paraffin
histology and sections stained with hematoxylin and eosin.
Control skin (FIG. 4a and 40) show few apparent neuron
bundles whereas A-56 Fl transgenic skin (FIG. 4b and 4d)
shows numerous, enlarged ?ber bundles.

The present invention provides transgenic mice that

region was linked to mouse NGF cDNA.

from the human epidermal K14 gene promoter and enhancer
sequences.
FIG. 1(b) shows a schematic depicting the onset of NGF
expression by E11, and its rise and fall at E15.
FIG. 1(0) shows mice screened for the transgene by
Southern hybridization of DNA isolated from tail samples

FIGS. 3a-d: FIG. 3 shows cellular expression of the
K14-NGF transgene in skin from A-56 F1 transgenics was
examined by in situ hybridization. Basal cells (arrows) in

DESCRIPTION OF THE INVENTION

manufacture increased levels of nerve growth factor (NGF)
in the basal keratinocytes of the skin.

BRIEF DESCRIPTION OF DRAWINGS

using a 32P-labeled DNA sequence complementary to the

The plasmid containing k14-NGF-hGH has been depos
ited with the American Type Culture Collection under the
terms of the Budapest Treaty and is available as Accession
No. 69423.

(d) allowing said embryo to develop to term.
Furthermore, the invention provides a method of testing

trigeminal sensory, the superior cervical sympathetic, and
the dorsal root ganglia were markedly enlarged.
The nerve growth factor expressing transgenic mice of the
present invention are valuable to researchers that study the
role of nerve growth factor and other neurotrophic factors in
the development and function of the nervous system, and in
the study of neurodegenerative disorders of the brain such as
Parkinson’s syndrome and Alzheimer’s disease.
To investigate the role of NGF in the development of the
peripheral nervous system and skin innervation, the human
K14 gene promoter was used to drive the expression of the
NGF cDNA in basal keratinocytes. Results show that target
derived overexpression of NGF has profound effects on the
level of skin innervation and neuronal survival.
Below is a more detailed outline of experimental proce
dure. NGF cDNA was linked to the promoter and enhancer

regulatory regions of the human keratin 14 gene. The
K14-NGF fusion gene was expressed at approximately

embryonic day 14, the time at which endogenous NGF
65

levels begin to decline and programmed neuronal death
begins. In situ hybridization of skin of K14-NGF transgenics
had increased levels of NGF mRNA in the basal cells of the
epidermis and associated hair follicle structures. The

5,602,309
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increase in target derived NGF mRNA was correlated with

To verify that the tissue distribution of K14-NGF expres
sion was comparable, RNA was analyzed from tongue,
brain, heart, liver, and kidney of an A-56 Fl transgenic and
nontransgenic control. Expression of the K14-NGF trans
gene was restricted to the keratinized epithelium samples

a hypertrophy of peripheral sensory and sympathetic nerves,
hyperinnervation of the skin, and a 26-1 17% increase in the
number of primary sensory neurons in the trigeminal gan
glion.

4

examined, skin (FIG. 2, lane 5) and tongue (lane 6). The

These results demonstrate that the level of NGF produc
tion by the target tissue dictates the level of neuron survival,
and in so doing, in?uences the distribution and number of

endogenous NGF transcript was detectable in skin (lanes 5

and 11), tongue (lanes 6 and 12), brain (lanes 7 and 13), heart
(lanes 8 and 14), and kidney (lanes 10 and 16) of both the
control and transgenic tissues. Liver tissues (lanes 9 and 15)
showed no evidence of NGF expression.

neurons in the adult.

Expression of K14-NGF in Skin of Transgenic

Cellular expression of the K14-NGF transgene was exam

Mice

mice using a fusion gene construct in which the human

ined using in situ hybridization on sections of whisker pad
skin, a region known to have a high level of innervation
(FIG. 3). A 35S-labeled cRNA probe speci?c for the mouse

epidermal K14 keratin promoter and enhancer sequences

NGF mRNA was hybridized to skin sections of 4 week-old

were linked to a mouse NGF cDNA (FIG. 1a). The K14

K14-NGF transgenics and non-transgenic siblings and pro
cessed for autoradiography. Few autoradiographic grains

NGF was overexpressed in the epidermis of transgenic

promoter has previously been shown to direct high level of
expression of various transgenes to basal keratinocytes of

were observed in the control skin (FIG. 3a) whereas the

the epidermis. (See Vassar, R., Rosenberg, M., Ross, 8.,

K14-NGF skin showed dense hybridization in the epidermal

Tyner, A. & Fuchs, E. (1989). Tissue-speci?c and differen

basal cell layer with decreasing intensity in suprabasal layers

tiation-speci?c expression of a human K14 keratin gene in

(FIG. 3b). Dense hybridization was also found in epidermal

transgenic mice. Proc. Natl. Acad. Sci. 86, 1563-1567; and
Vassar, R., Coulombe, P. A., Degenstein, L., Albers, K. & E.
Fuchs (1991). Mutant keratin expression in transgenic mice

cells of the outer root sheath of hair and vibrissa follicles of
25

causes marked abnormalities resembling a human genetic

skin disease. Cell 64, 365—380).

ter, 1982; Kopan and Fuchs, 1989).

The rationale in designing the K14-NGF construct is
based on the temporal overlap of NGF down-regulation with
the initiation of K14 expression, i.e., as the concentration of
target derived NGF beings to fall and neuronal cell death

30

Histological Examination of NGF Levels

commences (El4-El5, see FIG. 1(b)), the K14-NGF trans

To determine whether the increased level of N GF mRNA

gene turns on, producing elevated levels of NGF during the
critical period of cell death and thereafter in the adult (FIG.

112).

transgenic mice (FIG. 3d), but not in the corresponding areas
of nontransgenic (FIG. 30). The epidermal and hair follicle
distribution of hybridization is consistent with the known
expression pattern of the K14 keratin (Schweizer and Win

in the transgenic epidermis was processed into functional
35

NGF peptide, the skin of the transgenics was examined for
evidence of increased neuronal survival. Histological exami

Three founder mice have been isolated that express the

nation of skin from various regions of the body (dorsum,

transgene (FIG. 10). Founder A-39 (FIG. 1c, lane 1) and

ventral, tail, ear locations) revealed an increase in nerve
processes and an abundance of large nerve bundles coursing

founder A-56 (lane 3) were smaller and exhibited a lower

rate of weight gain when compared to their nontransgenic
siblings, whereas founder A-48 was normal in size. Fl

40

oifspring of founder A-56 also exhibited reduced weight
gain. Founder A-39 has not generated transgenic offspring,

(FIG. 4a, control; 4b, transgenic).
To con?rm that these structures were composed of neu

ronal processes, whisker pad skin from A-56 Fl mice was
immunolabeled with an antibody directed against the 150

though approximately eighty offspring have been screened.
The A-56 transgenics also had delayed eye opening (at least
2-3 days later than nontransgenic siblings) and frequently

throughout the papillary and reticular layers of the dermis

45

Kd neuro?lament protein (FIG. 4c, control; 4d, transgenic).

under low level lighting they retained a squinting appear

In control mice, neuro?lament positive ?bers and bundles
were evident in the reticular and deep layers of the dermis.
Occasional small positive ?bers could also be found pen
etrating the lower layers of the epidermis and in association

ance.

with hair follicle and vibrissa structures.

The relative level of K14~NGF expression in the three
founders was determined using Northern hybridization
analysis of total RNA isolated from full thickness skin (FIG.

A striking increase in the density and size of neuronal
processes was apparent in skin of A-56 transgenics (FIG.

exhibited a “squinty” appearance. This phenotype does not
appear to be due to an increase in light sensitivity since even

4d). Hyperinnervation was clearly evident in the papillary

2). Nontransgenic control skin samples (FIG. 2, lane 1) had
a single faint band hybridizing with the radiolabeled NGF
probe at approximately 1.3 kb, a size corresponding to the

55

endogenous RNA transcript.
RNA samples isolated from the A-39 (lane 2), A48 (lane
3), and A-56 (lane 4) skin contained, in addition to the
endogenous transcript, a 1.9-kb band that corresponded to
the predicted size of the K14-NGF transcript. Line A-39 and
A-48 had comparable levels of transgene expression
whereas expression in the A-56 line was signi?cantly higher.
Previous studies using the K14 promoter and enhancer
region to express other transgenes of interest have shown
transgene expression restricted to stratified, keratinized tis
sues such as skin, tongue, esophagus, and forestomach.

and reticular layers of the dermis as well as around hair
follicle structures. Hyperinnervation was also apparent in
skin of A-48 Fl mice, though at a reduced level than in the

A-56 transgenics.
Two primary sources of axons for the observed whisker

pad hyperinnervation are sensory neurons originating in the
60

trigerninal ganglion and sympathetic postganglionic ?bers
arising from the superior cervical ganglion. As a ?rst step in
determining the contribution from these two sources, immu
nocytochemistry was performed using antibodies directed
against the neurotransmitter calcitonin gene related peptide

65

(CGRP), for identi?cation of sensory neurons and the cat

echolamine-synthesizing enzyme tyrosine hydroxylase
(TH), for identi?cation of postganglionic sympathetic
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axons. (See Gibbins, I. L., Fumess, J. B., Costa, M., Macln~
tyre, I., Hillyard, C. J. and Girgis, S. (1985). Colocalization
of calcitonin gene-related peptide-like immunoreactivity

TABLE 1

with substance P in cutaneous, vascular and visceral sensory

Case Number

neurons of guinea pigs. Neurosci. Lett. 57, 125-130).

0401 Non-transgenic
0401 K14-NGF transgenic
0527 Non-transgenic
0527 K14-NGF transgenic
0513 Non-transgenic
tide general somatic sensory innervation: cutaneous and 10 0513 Kl4-NGF transgenic

CGRP is enriched in sensory nerves projecting to hair

follicles and as free endings in the epidermis. (See Kruger,
L. Silverman J. D., Mantyh P. W., Stemini, C., Brecha, N. C.
(1989). Peripheral patterns of calcitonin gene-related pep

Number of

Percent

Age

Neurons

Difference

24 d
24 (1
29 d
29 d
36 d
36 d

26,054
40,285
26,493
57,767
28,867
36,562

55

117
26

deep terminations. J. Comp. Neurol. 280, 291-302; and
A transgenic mouse model system was used to study the

Shotzinger, R. J ., and Landis, S. C. (1990). Postnatal devel~
opment of autononric and sensory innervation of thoracic

hairy skin in the rat. Cell Tissue Res. 260, 575-587).

Though CGRP staining has been reported in sympathetic
ganglion, it is thought to represent afferent input, not CGRP
production by ganglionic neurons. In control skin (FIG. 5a),
few CGRP-positive ?bers could be identi?ed. In contrast,
the K14-NGF transgenic skin had numerous small and large
bundles of CGRP-labeled ?bers throughout the dermis,
particularly in regions beneath the epidermis where abun

20

ron populations had increased survival is consistent with the
known dependence of these cells on NGF. Sensory neurons

dant axons terminations occur (FIG. 5b).

Sympathetic innervation of transgenic skin was enhanced
as shown by an increase in TH-immunoreactive ?bers (FIG.

25

6c, control; 6d, transgenic). Much of the increased TH
labeling was on ?ber bundles in the upper regions of the

dermis that also labeled for CGRP. TH-positive ?bers
appeared different from CGRP positive ?bers however, in
being thin, with numerous swellings. CGRP ?bers were

30

thicker and more uniform. Further distinction between
CGRP labeled and TH labeled ?bers was found in exami
35

J. (1983). Merkel cell distribution in the epidermis as

determined by quinacrine fluorescence. Cell Tissue Res. 228,
51-54). Sensory, but not sympathetic neurons, recognize
and associate with Merkel cells. (See Vos, R, Stark, E, and
40

It was found that TH and CGRP can be upregulated by
45

1(b). (See Davies, A. M. and A. Lumsden, (1984). Relation
of target encounter and neuronal death to nerve growth
50

It was also found that NGF induces hypertrophy of
55

tide to neurons in the epidermal target ?eld of the transgen~
ics was further indicated by a striking hypertrophy of the

trigerrrinal ganglion and the branches emanating from it.
60

than nontransgenic age-matched controls (Table 1 below).
The hypertrophy of the trigenrinal ganglion was also
reflected by the enlargement of the primary branches of the
transgenic nerve bundle (branch) is clearly larger than the
control.

factor responsiveness in the developing mouse trigeminal
ganglion. J. Comp. Neurol. 223, 124-137). These values are
twice that measured at postnatal day four, a result consistent
with the neurotrophic theory that up to half of all sensory

muscle layer, a location consistent with their sympathetic

trigeminal nerves. In the maxillary division of the trigeminal
nerve dissected from control and transgenic samples, the

NGF. During normal development, the maximum number of
cells in the trigeminal ganglia are found at E13 (see FIG.

nature.

Cell counts made of ganglia isolated from three A-56 F1
transgenics had values that ranged from 26 to 117% greater

Yip, J. W. (1981). Neuronal death in the spinal ganglia of the
chick embryo and its reduction by nerve growth factor. J.
Neurosci. 1, 60-71; and Stockel, L., Schwab, M. E., Thoe
nen, H. (1975). Comparison between the retrograde axorral
transport of nerve growth factor and tetanus toxin in motor,
sensory and adrenergic neurons. Brain Res. 89, 1-16).

with Merkel cells of the whisker follicle whereas no TH

trigenrinal ganglion. The availability of elevated NGF pep~

skin to cell bodies. Both sensory and sympathetic nerves
have been shown to take up labeled NGF and transport it

retrogradely. (See Hamburger, V., Brunso-Bechtold, J. K.,

neurons. Dev. Biol. 144, 281-300). In transgenic and control
samples only CGRP labeled ?bers could be found associated

between the control and transgenic samples in the deep
dermis. Few TH-immunoreactive ?bers could be found in
the deep dermis and these ?bers were frequently associated
with blood vessels that were adjacent to the underlying

both sensory and sympathetic neurons would be exposed to
elevated NGF at critical times in their development. Nerve
terminals of both sympathetic and sensory neurons would

duced by the transgenic epidermis and transport it from the

A., Mearow, K. M., Homes, M., Visheau, B., and Diamond,

labeling was evident.
It was found that TH and CGRP synthesis is enhanced by
NGF. No di?ference in TH-labeling could be discerned

are most dependent during embryonic development (shortly
before birth) whereas sympathetic neurons require NGF
within a 304 week period after birth. (See Levi~Montalcini
and Booker, 1960, supra; Johnson et a1., 1980, supra).
Since expression of the Kl4-NGF transgene begins at
E14-E15, rises, and continues at a steady level in the adult,

presumably have access to a greater amount of NGF pro~

nation of Merkel cells of vibrissa structures. (See Nurse, C.

Pittman, R. N. (1991). Merkel cells in vitro: Production of
nerve growth factor and selective interactions with sensory

role of target ?eld-derived NGF in development of the
peripheral nervous system. Elevation of the production of
NGF by the epidermal target tissue caused a dramatic
increase in neuronal survival as evidenced by a striking
hyperinnervation of the skin and hypertrophy of the trigemi
nal ganglia. Both sensory and sympathetic neurons in the
transgenic skin appeared to be rescued by the increased NGF
production as evidenced by enhanced CGRP- and TH
immunoreactivity. That both sensory and sympathetic neu

neurons produced during development die as the animal
matures. The trigeminal ganglia of mice expressing the
K14-NGF transgene had up to double the number of cells
than present in control mice.
Since the addition of exogenous NGF is known to block
sensory neuron death, the most likely explanation for the
increased cell number in the transgenic ganglia is that the
supernormal levels of NGF generated by K14NGF trans gene
expression in the target prevented cell death. Another pos
sibility is that additional neurogenesis was induced by
increased levels of NGF. Recent studies have suggested that
NGF can act as a rrritogen in the anterior pituitary and as a

65

meiotic growth factor during spermatogenesis. (See Borrelli,
E., Sawchenko, P. D. Evans, R. M. (1992). Pituitary hyper
plasia induced by ectopic expression of nerve growth factor.
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Proc. Natl. Acad. Sci. USA. 89, 2764—2768; and Parvinen,

increased target-derived NGF on cell survival. The results
demonstrate that the increased expression of NGF in the

M., Pelto-Huikko, M., Soder, 0., Schults, R., Kaipia, A.,
Mali, P., Toppari, J ., Hakovirta, H., Lonnerberg, P., Ritzen,
E. M., Ebendal, T., Olson, L., Hokfelt, T., Persson, H.

developing epidermis can inhibit, if not completely block,
neuron cell death. Moreover, the increase in the number of
surviving neurons was independent of changes in the vol
ume of the skin or number of cells in the target tissue (in this

(1992). Expression of B-nerve growth factor in rat semin—
iferous epithelium: speci?c function at the onset of meiosis.

J. Cell Biol. 117, 629-642).

case the skin) indicating the trophic factor alone can regulate
the number of surviving axons.

However, if NGF does exert a mitogenic effect on periph
eral neurons it must occur prior to the ?rst four-to-six weeks

These results support the neurotrophic hypothesis and
speci?cally demonstrate that the skin, by regulating the
timing and amount of NGF expression independent of

of postnatal development (the age at which animals were
examined), since we observed no mitotic ?gures in the
trigeminal ganglia despite examination of over 4000 cells/
ganglia. In addition, the K14-NGF transgene is active after
the period of normal cell birth and at a time when sensory
neurons have completed their migration and extended pro

innervation plays a central role in the development of the
peripheral nervous system.

cesses into the periphery. Typically, sensory neurons that are

EXAMPLE 1

EXAMPLES

this highly differentiated do not undergo neurogenesis. (See
Pannese, E. (1974). Adv. Anat. Cell Biol. 47, 1).
In addition to the apparent sensory neuron hyperinnerva
tion, some of the increased innervation resulted from

Construction of K14-NGF transgene and introduction into

mice. Plasmid pKS-NGF (a gift from R. Edwards, U.C.L.A.)
20

increased survival of NGF responsive sympathetic postgan
glionic neurons that innervate blood vessels, sweat glands,
and the erector pili muscles associated with hair follicles.
Sympathetic neuronal cell bodies that innervate the whisker
pad skin are located in the superior cervical ganglion, a
structure that was also enlarged in the K14-NGF transgenics.

the BamHl cut, Klenow ?lled K14-hGH cassette vector

(Vassar and Fuchs, 1991, supra). Dr. Elaine Fuchs (Univer
sity of Chicago) provided the K14-hGH plasmid.

The increase in tyrosine hydroxylase irnrnunoreactivity was

K14-hGH contains 2.1 kbp of 5 ' upstream sequence of the

restricted to the ?ber bundles in the super?cial portion of the
dermis. Blood vessels which normally receive a few

intensely stained TH-positive ?bers appeared to have the

30

same low level of sympathetic innervation in the transgenic
mice. These blood vessels are well removed from the basal

keratinocytes expressing the NGF transgene suggesting the
hyperinnervation is supported only for those structures near
the site of NGF overproduction.

35

The hyperinnervation of a target may be dependent on
factors other than increased expression of NGF. Merkel cells
are abundant in vibrissae structures and receive sensory

input. In the K14-NGF transgenics, a large increase in the
number of CGRP-positive ?bers projecting to these cells

was cut with Apa 1 (+230) and Pst l (+1027) to remove a

797 base pair fragment that encodes the NGF short transcript
(Edwards et al., 1989). The overhanging ends of the Apa
l-Pst l NGF fragment were removed using mung bean
nuclease and the fragment was gel puri?ed and ligated into

40

human K14 keratin gene and a 1.8 kbp intron containing
sequence from the human growth hormone (hGH) gene. The
hGH sequence serves to upregulate expression of the trans

gene and provides a polyadenylation signal. (See Sandgren,
E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L. & Lee,
D. C. (1990). Overexpression of TGF alpha in transgenic
mice: Induction of epithelial hyperplasia, pancreatic meta
plasia, and carcinoma of the breast. Cell, 61, 1210-1135).
The S-kbp EcoRl kl4-NGF-hGH fragment (FIG. 1a) was
isolated on 0.8% Seaplaque agarose gel (FMC Corporation),
extracted from the gel using glassmilk puri?cation
(Geneclean Bio 101), and run through a NACS column

(Bethesda Research Laboratories).

was found. No TH~positive ?bers were seen projecting to

these cells even though large numbers of TH-positive axons

The plasmid used to transfect mouse cells according to the

were seen in nerve bundles immediately adjacent to the

present invention kl4‘NGF-hGH has been deposited with
the American Type Culture Collection under the terms of the
Budapest Treaty and is available as Accession No. 69423.
DNA was ethanol precipitated, resuspended in phosphate

vibrissae. These results agree with experiments reported by
Edwards et al. in which the rat insulin promotor was utilized
to overexpress the NGF cDNA in islet cells of the pancreas.

45

(See Edwards, R. H., Rutter, W. J., Hanahan, D. (1989).

buffered saline at a concentration of 5 pg/ml, and injected

Directed expression of NGF to pancreatic B cells in trans
genic mice leads to selective hyperinnervation of the islets.

into fertilized C3HB6 mouse (Harlan Laboratory Supplies)
embryos. Injections and implantations were carried out

Cell 58, 161—170).

using standard procedures. (See Hogan, B., Costantini, F. &
Lacy, E. (1986). Manipulating the Mouse Embryo: A Labo
ratory Manual (Cold Spring Harbor Press, Cold Spring

Hyperinnervation of the pancreas was observed, though
the sole source of innervating ?bers appeared to be sympa
thetic postganglionic neurons. No apparent effect of

Harbor, NY.)

increased NGF was observed on sensory ?bers. From this 55

?nding it was proposed that the selective affect on sympa
thetic axons was due to unidenti?ed cofactors that supported
hyperinnervation of the sympathetic but not sensory axons.
This type of mechanism may have relevance to another

transgenic mouse expression study in which the prolactin

Mice were screened for the transgene using Southern
hybridization analysis on DNA extracted from tail or by

employing the polymerase chain reaction on DNA samples
isolated from ear punches. For Southern hybridizations, 10
ug of DNA was digested with Pst 1, separated on an 0.7%
60

promotor was utilized to target NGF expression to the

anterior pituitary, a tissue not normally innervated. Though

agarose gel, transferred to nitrocellulose by blotting and
probed with a random primed 32P-dCTP (New England
Nuclear) labeled probe made to the full length NGF cDNA.

an increased amount of NGF was synthesized, the anterior

pituitary was not innervated, i.e., NGF did not induce
innervation of an inappropriate target.
The expression paradigm used has allowed an examina
tion of the neurotrophic hypothesis and the eifect of

EXAMPLE 2
65

Analysis of mRNA expression by Northern hybridization.
Northern analysis was performed on RNA that was isolated

from various tissues using guanidium thiocyanate/ phenol/
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chloroform extraction. (See Chomczynski, P. & Sacchi, N.
(1987). Single-step method of RNA isolation by acid guani

dorsal root ganglion cells. J. Neurosci. Methods 35,

dinium thiocyanate-phenolchlorofonn extraction. Analyt.
Biochem. 162, 156-159).

This method is based on a determination of the number of
neuronal nucleoli. Animals were placed under deep anes

187-194.).
thesia and perfused transcardially with 4% paraformalde

Fifteen micrograms of total RNA was resolved on a 1.2%

hyde in 0.1M phosphate buffer, pH 7.4. Trigeminal ganglia

agarose formaldehyde denaturing gel, transferred to Nytran
membrane (Schleicher and Schuell) by blotting, baked 2 h in

were removed and immersion ?xed in 4% paraformalde

a vacuum oven at 80° C., and then hybridized to a 32P-dCTP

hyde, dehydrated in alcohol, defatted and embedded in

labeled random primed probe made to the full length NGF
cDNA.

'

10

tube was used to trace the outline of the section and to

EXAMPLE 3

demarcate the location of each sensory neuron containing a

In situ hybridization. 35S-labelled cRNA probes were

generated by adding lug of linearized pKS-NGF plasmid

nucleoli. To compensate for neurons with two or more
15

nucleoli, pro?les of randomly selected neurons were recon
structed and the total number of nuclei per 100 neurons was
determined. This provided a ration of nucleoli/neuron that
was multiplied by the total neurons counted to obtain the
total number of neurons per ganglion (Coggeshall et al.,

20

1990, supra).

(linearized with Sac l for an antisense probe and EcoRl for
a sense probe) to 2.5mM each ATP, CTP, GTP, 15 mM

[35S]UTP (New England Nuclear) and either T7 or T3
polymerase (Stratagene) to generate antisense and sense
probes, respectively. Incubation was for 60 min at 40° C. in

para?in. Entire ganglia were serial sectioned at 6 pm and
stained with hematoxylin and eosin. Every tenth section was
examined at a total magni?cation of 400x and a drawing

transcription buffer containing 50 mM MgCl2, 20 mM
spermidine, 20 mM Tris (pH 7.4) and 10 mM DTT. The

EXAMPLE 5

solution was phenol1chloroformextracted and precipitated
with ammonium acetate and 2.5 volumes of ethanol in the

dissected, immediately frozen on dry ice, cryostated at

Immunohistochemistry. Tissue was immersed in ?xative
for 90 min., transferred to 20—30% sucrose in phosphate
buffered saline (PBS) and incubated overnight at 4° C.
Samples were cryostated at 10 pm, thaw-mounted onto
Vectabond-coated glass slides and processed for immuno

10-20 pm, mounted onto Vectabond-coated slides (Vector

cytochernistry.

presence of 25 pg carrier tRNA.
For in situ hybridization, mouse whisker pad skin was

25

Labs) and stored at —80° C. until hybridized. To hybridize,
slides were brought to room temperature, ?xed for 10 min in

Sections were incubated with primary antibody (diluted in
PBS containing 1% normal goat serum and 0.3% Triton
X-l00), 18-24 h at 4° C. in a humidi?ed chamber, rinsed in
PBS for 30 min (3 changes), incubated in a secondary

4% paraformaldehyde, washed in diethyl pyrocarbonate
(DEPC)-treated phosphate buffer, transferred to 0.25% ace~
tic anhydride in 0.1 M TEA (pH 8/0) for 10 min at room
temperature, dehydrated through a graded series of alcohols

antisera consisting of appropriate ?uorophore~conjugated
IgG immunoglobulins (diluted in PGC with 0.3% Triton

and defatted in chloroform. Sections were hybridized for 35 X-100; l h at room temperature), rinsed in PBS, and
12-24 hr at 60° C. in a hybridization solution consisting of
coverslipped.

IXIOTM cpm/ml of 35—labeled cRNA probe, 50% formamide,
1X Denhardt’s solution, 200 mMTris (pH 7.5), 10% dextran
sulfate, 0.3 ug/ml salmon sperm DNA, 0.15 mg/ml tRNA,

Primary antibodies recognizing the following proteins

and 40 mM DTT. Slides were washed in 4><SSC (1XSSC= 40

0.15M NaCl, 0015M sodium citrate, pH 7.0), incubated in
20 mg/ml ribonuclease A (Sigma) dissolved in 10 mM
Tris-saline, and then washed through descending concentra
tions of SSC. The ?nal wash was with 0.1><SSC at 37° C. for
1 hour. Sections were air~dried and placed in X-ray cassettes

45

ondary antibody (Cappel Laboratories). Visualization of
CGRP and TH irnmunoreactivity was achieved using avidin

biotin~peroxidase complex (ABC) kit from Vector Labora
tories.

dried and exposed to ?lm. Emulsion dipped slides were
50

Pennount.
Skin sections from transgenic mice and nontransgenic

siblings were processed in parallel. Controls for probe
speci?city included hybridization using a sense cRNA probe

(CGRP; 1:200 dilution; Chemicon), tyrosine hydroxylase
(TH; 1:100 dilution; Chernicon).
Binding of the neuro?lament antibody was visualized
using anti-rabbit ?uorocein isothiocyanate conjugated sec

with Hyper?lm B-Max X-ray ?lm (Amersham). Films were
exposed for 3-7s and developed in Kodak D-l9. Selected
slides were dipped in Kodak NTB-2 liquid emulsion, air
developed in D19, ?xed in Kodak rapid ?xer, counterstained
with hematoxylin/eosin or cresyl violet and coverslipped in

were used: anti-150 Kd neuro?lament protein (NE 150;
1:300 dilution; Chemicon), calcitonin gene related peptide

55

and pretreatment of tissue with RNase. Both of these con

After primary antibody incubation, sections were washed
twice in PBS (5 min. each) incubated in biotinylated goat
anti rabbit secondary antibody for 30 min., washed in PBS
and incubated in the ABC complex for 30 min. following
two PBS Washes, immunoreactivity was visualized by incu
bation in 0.025% 3,3'—diaminobenzidine-4HC1 (Aldrich)
with 0.05% H202 and 1.5% nickel ammonium sulfate dis
solved in 0.1M sodium acetate buffer, pH 6 for 7 minutes.

ditions resulted in the absence of hybridization.

EXAMPLE 6

To test the efficacy of drugs in treating neurodegenerative

EXAMPLE 4

60 disorders, a drug candidate is administered to a mouse

Cell counts of tn'geminal neurons. Cell counts were

according to the invention. The behavioral effects and tissue

obtained using the method of Coggelshall et al. (See Cog

changes of the mouse are determined upon administration of

gelshall, R. E., Chung, K., Greenwood, D., Hulsebosch, C.
(1984). An empirical method for converting nucleolar

the drug.

counts to neuronal numbers. J. Neurosci. Methods 12,

125-132; Coggelshall, R. E., La Forte, R., and Klein, C. M.
(1990). Calibration of methods for determining numbers of
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DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1 Transgene Construct and characterization of trans

genic expression
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FIG. 1(a) shows the K14-NGF fusion gene contains the
mouse NGF cDNA cloned downstream of the human epi
dermal K14 gene promoter and enhancer sequences (Vassar

FIG. 4 Expression of K14-NGF causes hyperinnervation
of skin.

et al., 1989). A fragment containing a partial sequence of the

hyperinnervation that was evident with normal histology.

hGH gene was ligated downstream of the NGF insert to

Skin from dorsum, (FIGS. 4a and 4b) and whisker pad (FIG.
4c and 4a’) was processed for para?in histology and sections
stained with hematoxylin and eosin. Control skin (FIG. 4a

Overproduction of NGF by the epidermis caused by

provide an intron containing sequence and poly A (pA)
addition signal. Arrow indicates transcription start site. FIG.
1(b) shows a schematic depicting the onset of NGF expres~
sion by E11, and its rise and fall at E15. As the endogenous
level of NGF decreases, expression of the K14-NGF trans
gene begins, rises to a steady level and continues in the adult
skin. Actual relative levels of expression are not implied.
FIG. 1(a) shows mice were screened for the transgene by

and 40) had few apparent neuron bundles whereas A-56 Fl

transgenic skin (FIG. 4b and 4d) showed numerous,
enlarged ?ber bundles (arrowheads. * =muscle. BaFlO um.
FIG. 5 Immunolabeling of transgenic skin reveals a
hyperinnervation of sensory and sympathetic neurons.
To verify that the ?ber bundles in the skin were composed
of neuronal processes, frozen sections of whisker pad skin

Southern hybridization of DNA isolated from tail samples
obtained three to four weeks after birth. Blots were probed

using a 32P-labeled DNA sequence complementary to the

from control (FIG. 5a) and A-56 Fl transgenics (FIG. 5b)

mouse NGF cDNA. The NGF probe detects both the trans

were immunolabeled with an antineuro?lament 150 anti

gene at 1.8 kbp (arrowhead) and the single copy, endogenous
NGF gene (1.58 kbp band below the transgene). Three
founder animals were isolated: Lane 1, A-39; Lane 2, A-47;
Lane 3, A-56; Lane 4, nontransgenic control.
FIG. 2 Expression of the K14-NGF transgene is tissue

body followed by incubation with a goat anti-rabbit FITC
20

speci?c
FIG. 2(a) examines the expression level of the K14-NGF
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transgene for each line. RNA was isolated from full thick
ness skin of 4-6 week-old Fl mice and analyzed using
Northern hybridization. Ten micrograms of total RNA was
resolved on a formaldehyde denaturing gel, transferred to

biotinylated goat-anti rabbit secondary processing with

were loaded onto a single gel. Two ?lm exposure were done

CGRP followed by a biotinylated goat-anti rabbit secondary
antibody (FIG. 5d). Large numbers of CGRP positive ?bers

in order to detect the low level expression of endogenous
35

corresponding to the endogenous NGF transcript; lane 2,
RNA from tail skin of A-39 founder. Transgene mRNA band
(arrowhead) is apparent at the predicted size of 1.9 kb; lane
3, skin RNA ofA~47 F1, lane 4, skin RNA ofA-56 Fl, lane
5, skin RNA of A47 F1 (loaded twice); lane 6, tongue RNA
of A-56 Fl. Tongue is a keratinized, K14 keratin expressing
structure expected to have transgene expression.
FIG. 2(b) examines the tissue speci?city of K14-NGF

expression. RNA from brain (lane 7, A-56; lane 13, control),
heart (lane 8, A-56; lane 14, control), liver (lane 9, A-56,
lane 15, control), and kidney (lane 10, A-56; lane 16,

cervical ganglia, controls (left) were smaller than either the
45

will so fully reveal the general nature of the invention that
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ments without departing from the generic concept and
therefore such adaptations are intended to be comprehended
within the meaning and range of equivalents of the disclosed
embodiments. It is to be understood that the phraseology or

terminology employed herein is for the purpose of descrip
tion only and not of limitation. It is obvious that certain

changes and modi?cations may be practiced within the
scope of the appended claims.
We claim:
1. A transgenic mouse whose somatic and germ cells
contain and express a gene encoding for mouse nerve
60

skin. Basal cells (arrows) in whisker pad epidermis, FIG.
3(a), and vibrissa, FIG. 3(0), of control animals had silver
grain density at background levels. A-56 F1 transgenic mice
had a greater labeling density of whisker pad basal cells,
izations using a sense riproprobe showed background levels
of hybridization. Bar=50 pm.

A-48 (center) or A-56 ganglia (right. Bar=1 mm).
The foregoing description of the speci?c embodiments

others can, by applying current knowledge, readily modify
and/or adapt for various applications such speci?c embodi

FIG. 3 K14-NGF transgene produces elevated levels of

FIG. 3(b) (arrows), and vibrissa, FIG. 3(d). Control hybrid

vibrissa. Inset shows vibrissa surrounded by CGRP positive
?bers (arrowheads). Bar:5 um.
FIG. 6 Expression of K14~NGF causes enlargement of the

glia (FIG. 6b) were removed from control A-48 F l, and A-56
F 1 mice. For both the trigeminal and sympathetic superior

and 18s ribosomal RNA size markers are indicated by bars
on right.
NGF mRNA in skin.
FIG. 3 shows cellular expression of the K14-NGF trans
gene in skin from A-56 F1 transgenics was examined by in
situ hybridization. 35S-labeled cRNA sense and antisense
probes were hybridized to frozen sections of whisker pad

and nerve bundles were present in the dermis and around

trigeminal and superior cervical ganglia.
Trigeminal ganglia (FIG. 6a) and superior cervical gan

control) were tested. Transgene expression was not evident

in these structures, though the l.3~kb endogenous NGF
transcript could be detected in all but liver samples. Lane 11,
control skin RNA; lane 12, control tongue RNA. The 28s

signi?cant increase in the number of ?bers and bundles was
seen in an equivalent region of A-56 transgenic skin (FIG.
512). To determine whether the large nerve bundles in the
A-56 skin contained sympathetic ?bers, sections were
immunolabeled with an anti-TH antibody followed by a

DAB (FIG. 5c). TH positive ?bers, which were rare in
control skin, were found throughout the dermis (arrow
heads). To examine peripheral sensory ?bers in the trans
genic skin, A-56 F1 transgenics were labeled with anti

Nytran membrane and probed with a 32P-labeled DNA
sequence complementary to the NGFrnRNA. All samples
NGF transcript. Shown is a 3 d exposure, FIG. 2(a) and a 10
d exposure, FIG. 2(b), of the same ?lter. Lane 1, skin RNA
of nontransgenic control. A faint band is visible at 1.3 kb

conjugated secondary. Control skin had immunoreactive
?bers (arrowheads) in the reticular layer of the dermis, deep
dermis, and around hair follicles and vibrissa (arrow). A

growth factor, said mouse exhibiting hyperinnervation when
compared to a normal mouse, and said gene having been
introduced into fertilized mouse embryo of said mouse or an

ancestor of said mouse by microinjection, and wherein said
gene is introduced into said mouse as plasmid kl4-NGF
65

hGH, deposited as of ATCC Accession.
2. The mouse of claim 1, wherein said mouse is fertile and

capable of transmitting said gene to its oifspring.

5,602,309
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3. The mouse of claim 1, wherein said plasmid k14-NGF
hGH comprises a 1.8 kbp sequence encoding the human

growth hormone gene.
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(a) providing a mouse nerve growth factor gene plasmid
kl4-NGF-hGH, deposited as of ATCC Accession No.

69423;

4. The mouse of claim 1, wherein said mouse has a

(b) introducing said gene into a fertilized mouse embryo

phenotype characterized by hyperinnervation of the skin,
hypertrophy of the trigeminal ganglion and enlargement of
the superior cervical sympathetic and dorsal root ganglia

(c) transplanting said embryo into a pseudopregnant

when compared to a normal mouse.

(d) allowing said embryo to develop to term.

by microinjection;
mouse; and

5. A method of producing the mouse of claim 1, which

comprises:
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